🔽European indices fell at the end of the session after several countries suspend use of AstraZeneca's vaccine
At the end of the European session, moods in the stock market worsened due to the negative news regarding coronavirus vaccination. Authorities in Germany, France and Italy today announced they are no longer using AstraZeneca vaccines. In response to these reports, the main stock indices on the Old Continent are trading at their daily lows. The German DAX (DE30) contract is losing more than 1% and is trading below 14,400 points, while the French CAC40 (FRA40) contract fell 0.75% and the Italian FTSE MIB (ITA40) is down 0.2%.
The World Health Organization, however, believes that there is no evidence which would suggest that cases of blood clots are related to the AstraZeneca vaccine, and the UK medicines agency said the vaccine is safe.
Start investing today or test a free demo
Create account Try a demo Download mobile app Download mobile appLooking at the technical situation at the DE30, sellers broke below the support at 14,450 pts, which may open the way towards bigger downward correction. As for the H1 interval, the nearest major support is at 14,260 pts and is marked with the lower limit of 1: 1 structure. The local formation of a double peak may herald further declines.
DE30 interval H1. Source: xStation5
The content of this report has been created by XTB S.A., with its registered office in Warsaw, at Prosta 67, 00-838 Warsaw, Poland, (KRS number 0000217580) and supervised by Polish Supervision Authority ( No. DDM-M-4021-57-1/2005). This material is a marketing communication within the meaning of Art. 24 (3) of Directive 2014/65/EU of the European Parliament and of the Council of 15 May 2014 on markets in financial instruments and amending Directive 2002/92/EC and Directive 2011/61/EU (MiFID II). Marketing communication is not an investment recommendation or information recommending or suggesting an investment strategy within the meaning of Regulation (EU) No 596/2014 of the European Parliament and of the Council of 16 April 2014 on market abuse (market abuse regulation) and repealing Directive 2003/6/EC of the European Parliament and of the Council and Commission Directives 2003/124/EC, 2003/125/EC and 2004/72/EC and Commission Delegated Regulation (EU) 2016/958 of 9 March 2016 supplementing Regulation (EU) No 596/2014 of the European Parliament and of the Council with regard to regulatory technical standards for the technical arrangements for objective presentation of investment recommendations or other information recommending or suggesting an investment strategy and for disclosure of particular interests or indications of conflicts of interest or any other advice, including in the area of investment advisory, within the meaning of the Trading in Financial Instruments Act of 29 July 2005 (i.e. Journal of Laws 2019, item 875, as amended). The marketing communication is prepared with the highest diligence, objectivity, presents the facts known to the author on the date of preparation and is devoid of any evaluation elements. The marketing communication is prepared without considering the client’s needs, his individual financial situation and does not present any investment strategy in any way. The marketing communication does not constitute an offer of sale, offering, subscription, invitation to purchase, advertisement or promotion of any financial instruments. XTB S.A. is not liable for any client’s actions or omissions, in particular for the acquisition or disposal of financial instruments, undertaken on the basis of the information contained in this marketing communication. In the event that the marketing communication contains any information about any results regarding the financial instruments indicated therein, these do not constitute any guarantee or forecast regarding the future results.
